Radimmune is developing antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary antibodies targeting extracellular accumulations of, normally, intracellular substances. Necrotic cancer cells found in rapidly growing tumors can lose membrane integrity and become leaky. In contrast, normal cells remain intact and do not release their intracellular contents. Because of the cell membrane changes in cancer cells, intracellular proteins and pigments become more readily accessible and are released into the space outside of and between cancer cells. Radimmune antibody-targeted radiation therapeutics can bind to the now accessible intracellular substances and kill nearby cancer cells. As the antibody-targeted radiation therapeutics kill more cancer cells, more and more of the target intracellular substance is released and the anti-tumor effect of repeated doses is amplified and perpetuated.
